Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benmelstobart plus Anlotinib vs Tislelizumab in Advanced Non-squamous NSCLC
NCT05346952Phase 3Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jan 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of benmelstobart, anlotinib in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Status: unknown.
02
Drugs
benmelstobartanlotinib
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT05346952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05346952.